Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: kidney
- Who it enrolls
- age 18 Years to no upper limit; no BMI minimum stated; conditions: Kidney Disease, Chronic; Diabetes; Dialysis; End Stage Kidney Disease (ESRD)
- Interventions
- Semaglutide Pen
- Conditions
- Kidney Disease, Chronic; Diabetes; Dialysis; End Stage Kidney Disease (ESRD)
- Phase and size
- Phase 4 · 100 participants
- Dates
- Start 2025-11-27
Primary completion 2027-07 - Sponsor
- Unity Health Toronto (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Adherence of Study Intervention26 weeks
02Eligibility
Who can take part
Inclusion Criteria: 1. Age ≥ 18 2. Receiving chronic maintenance hemodialysis or peritoneal dialysis for ≥ 90 days 3. confirmed DM2 based on medical history and current or prior receipt of an oral hypoglycemic agent and/or insulin. 4. Ability to provided informed consent or through their substitute decision maker Exclusion Criteria: 1. Type 1 DM 2. Use of a GLP-1-RA within 30 days prior to screening 3. Personal or first-degree relative(s) with a history of type 2 multiple endocrine neoplasia syndrome or medullary thyroid cancer, or acute pancreatitis (within 180 days of study screening) 4. Confirmed pregnancy, women of childbearing potential 5. Known hypersensitivity to GLP-1-RA 6. Expected to recover kidney function, stop hemodialysis, pursue palliative care, or transplantation within 6 months 7. Enrolment in another clinical trial judged by the investigator to interact with the effect of GLP1-RA
03Change log
Registry changes
No changes recorded since the trial was added.